GRAIL Inc (GRAL) AI Stock Analysis

• Market Cap: $3.55B
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.75
• Revenue Growth: 20.53%
• EPS Growth: 82.91%
• Country: US
• Employees: 1,000
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.46
• Shares Outstanding: 38,982,224
• 10 Day Avg. Volume: 1,009,555
• 30 Day Avg. Volume: 1,199,319
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.23
• Price to Sales (P/S): 4.53
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: 0.37
• Enterprise Value/Revenue: 9.17
• Enterprise Value/Gross Profit: -19.28
• Enterprise Value/Ebitda: -3.39
• 1Y Price Target: $60.86
• Price Target Upside: -27.30% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $110.00 ▲(31.41% Upside)

GRAIL Inc. demonstrates strong technical momentum and strategic growth initiatives, bolstered by recent financing and partnerships. However, profitability challenges and valuation concerns temper the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for GRAIL's products, supporting long-term market expansion and business sustainability.

Strategic Partnerships

The partnership with Samsung enhances GRAIL's market position in Asia, providing financial support and facilitating international expansion.

Financial Stability

The private placement improves liquidity and extends the cash runway, supporting operational needs and strategic initiatives into 2030.

Negative Factors

Profitability Challenges

Persistent negative margins highlight ongoing operational inefficiencies, potentially hindering long-term profitability and growth.

Regulatory Delays

Potential delays in FDA approval could impact product rollout and revenue growth, posing risks to strategic timelines and market entry.

Cash Flow Challenges

Negative cash flow indicates reliance on external financing, which could limit financial flexibility and increase vulnerability to market changes.

GRAIL Inc Business Overview & Revenue Model

Company Description

GRAIL Inc (GRAL) is a biotechnology company focused on early cancer detection through advanced genomic technologies. The company specializes in developing multi-cancer early detection (MCED) tests that utilize a proprietary platform to analyze blood samples for indicators of various cancers. GRAIL operates within the healthcare sector, leveraging cutting-edge science to provide innovative solutions aimed at improving patient outcomes and reducing cancer mortality rates.

How the Company Makes Money

GRAIL generates revenue primarily through the sale of its multi-cancer early detection tests to healthcare providers and institutions. The company's revenue model is driven by a combination of direct sales, partnerships with healthcare systems, and reimbursement strategies that allow patients to access testing through insurance coverage. Additionally, GRAIL may engage in collaborations with pharmaceutical companies for research and development, which can contribute to its earnings. The establishment of strategic partnerships with key players in the healthcare industry further enhances its market reach and potential revenue streams.

GRAIL Inc Financial Statement Overview

Summary

GRAIL Inc. shows strong revenue growth but faces significant profitability challenges with negative margins. The company maintains financial stability through a strong equity position and low leverage, but cash flow remains a concern due to negative free cash flow and reliance on external financing.

Income Statement

GRAIL Inc. has shown substantial revenue growth with a 34.89% increase from 2023 to 2024. However, the company continues to operate at a loss with a negative gross profit margin of -62.12% and a net profit margin of -161.42% in 2024. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

GRAIL Inc. maintains a strong equity position with an equity ratio of 83.92%. The debt-to-equity ratio is low at 0.03, signifying limited leverage. However, the return on equity is negative due to ongoing losses. The company's high stockholders' equity relative to total assets suggests financial stability but profitability remains a concern.

Cash Flow

The operating cash flow to net income ratio is 0.28, indicating cash flow challenges. Free cash flow has improved slightly, but remains negative at -$582.36 million. The company raised $1.24 billion in financing activities, aiding liquidity but highlighting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	141.83M	125.59M	93.11M	55.55M	14.61M	0.00
Gross Profit	-67.41M	-78.02M	-95.61M	-116.45M	-100.00M	0.00
EBITDA	-383.24M	-610.17M	-638.22M	-587.70M	-1.21B	-308.73M
Net Income	-406.24M	-2.03B	-1.47B	-5.40B	-1.25B	-312.16M
Balance Sheet
Total Assets	2.60B	2.98B	4.56B	5.60B	9.74B	706.30M
Cash, Cash Equivalents and Short-Term Investments	540.13M	763.47M	97.29M	241.60M	221.16M	583.48M
Total Debt	58.59M	68.14M	84.41M	96.01M	110.56M	62.99M
Total Liabilities	361.07M	479.90M	910.74M	955.94M	307.40M	144.46M
Stockholders Equity	2.24B	2.50B	3.65B	4.65B	9.43B	561.84M
Cash Flow
Free Cash Flow	-329.83M	-582.36M	-608.69M	-584.17M	-758.06M	-243.91M
Operating Cash Flow	-328.71M	-577.16M	-595.80M	-561.31M	-688.13M	-232.00M
Investing Cash Flow	-394.45M	-551.01M	-12.89M	-22.86M	344.81M	-12.79M
Financing Cash Flow	0.00	1.24B	463.77M	604.82M	394.74M	275.11M

GRAIL Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRAL, the sentiment is Positive. The current price of 83.71 is below the 20-day moving average (MA) of 97.86, below the 50-day MA of 88.81, and above the 200-day MA of 50.45, indicating a neutral trend. The MACD of 0.22 indicates Positive momentum. The RSI at 49.08 is Neutral, neither overbought nor oversold. The STOCH value of 23.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRAL.

GRAIL Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRA	73 Outperform	$32.08B	-103.13	-29.02%	―	38.17%	-28.77%
ILMN	71 Outperform	$20.59B	30.83	31.20%	―	-2.39%	―
GRAL	70 Outperform	$3.55B	-8.13	-16.83%	―	20.53%	82.91%
GH	61 Neutral	$12.90B	-31.54	―	―	30.38%	24.17%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
NEO	55 Neutral	$1.53B	-13.99	-12.99%	―	10.10%	-44.29%
MYGN	41 Neutral	$610.55M	-1.56	-72.52%	―	0.21%	-233.51%

GRAIL Inc Corporate Events

GRAIL Inc Announces $300M Equity Distribution Agreement

On November 13, 2025, GRAIL, Inc. filed a prospectus supplement with the SEC for the resale of 3,925,767 shares of common stock, which were issued to selling stockholders through a securities purchase agreement dated October 18, 2025. Additionally, on November 14, 2025, GRAIL entered into an Equity Distribution Agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, allowing the company to sell up to $300 million of its common stock through an ‘at the market’ offering. This strategic move is aimed at enhancing the company’s financial flexibility and market positioning.

GRAIL Inc Secures $325 Million in Private Placement

On October 18, 2025, GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement, expected to raise approximately $325 million. The proceeds will support GRAIL’s commercial activities, reimbursement efforts, and general corporate purposes, with the closing expected on October 21, 2025. This financing round includes participation from new and existing institutional investors and is anticipated to fund operations into 2030, excluding a separate $110 million investment from Samsung. The private placement is exempt from registration under the Securities Act, with GRAIL agreeing to file a registration statement for the resale of shares.

GRAIL Inc Partners with Samsung for $110M Investment

On October 16, 2025, GRAIL, Inc. entered into a stock purchase agreement with Samsung C&T Corporation and Samsung Electronics to issue and sell shares worth $110 million in a private placement. This strategic collaboration aims to commercialize GRAIL’s Galleri multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore. The agreement includes conditions such as regulatory approvals and the execution of business and strategic collaboration agreements by early 2026. This partnership is expected to strengthen GRAIL’s market position in Asia and provide financial support for its commercialization and reimbursement efforts.

GRAIL Inc Signs New Headquarters Lease Agreement

GRAIL, Inc. has entered into a commercial lease agreement for a new corporate headquarters in Sunnyvale, California, covering approximately 75,556 square feet. The lease, starting in October 2026 and ending in September 2037, includes an initial monthly rent of $449,558 with annual increases, and provides options for expansion and renewal.